- Home
- MCRB vs EPIX Comparison
MCRB vs EPIX Comparison
Compare MCRB & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- EPIX
- Stock Information
- Founded
- MCRB 2010
- EPIX 2009
- Country
- MCRB United States
- EPIX Canada
- Employees
- MCRB N/A
- EPIX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- EPIX Health Care
- Exchange
- MCRB Nasdaq
- EPIX Nasdaq
- Market Cap
- MCRB 72.0M
- EPIX 71.5M
- IPO Year
- MCRB 2015
- EPIX N/A
- Fundamental
- Price
- MCRB $7.05
- EPIX $1.68
- Analyst Decision
- MCRB Hold
- EPIX Hold
- Analyst Count
- MCRB 5
- EPIX 3
- Target Price
- MCRB $73.67
- EPIX $2.00
- AVG Volume (30 Days)
- MCRB 93.5K
- EPIX 138.8K
- Earning Date
- MCRB 05-07-2025
- EPIX 05-08-2025
- Dividend Yield
- MCRB N/A
- EPIX N/A
- EPS Growth
- MCRB N/A
- EPIX N/A
- EPS
- MCRB 8.98
- EPIX N/A
- Revenue
- MCRB N/A
- EPIX N/A
- Revenue This Year
- MCRB N/A
- EPIX N/A
- Revenue Next Year
- MCRB N/A
- EPIX N/A
- P/E Ratio
- MCRB $0.84
- EPIX N/A
- Revenue Growth
- MCRB N/A
- EPIX N/A
- 52 Week Low
- MCRB $6.53
- EPIX $1.40
- 52 Week High
- MCRB $30.60
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- MCRB 38.95
- EPIX 49.37
- Support Level
- MCRB $7.32
- EPIX $1.60
- Resistance Level
- MCRB $7.86
- EPIX $1.70
- Average True Range (ATR)
- MCRB 0.63
- EPIX 0.05
- MACD
- MCRB 0.10
- EPIX -0.01
- Stochastic Oscillator
- MCRB 28.89
- EPIX 53.33
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.